Noerr advises MediBeacon on acquisition in German market
Noerr has advised the US healthcare company MediBeacon on its acquisition of the German company Mannheim Pharma & Diagnostics, a life science company specialising in animal diagnostics.
Mannheim Pharma & Diagnostics owns a technology for measuring renal function in animals, which supplements MediBeacon’s IP portfolio. MediBeacon’s development activities focus on a system for monitoring human renal function, which is currently undergoing clinical tests. It enables physicians to constantly monitor patients’ renal function in real time.
Medibeacon has relied on the advice from Noerr and a cross-practice-group team led by Dr. Florian Becker, co-head of Noerr’s Corporate/M&A practice group. Noerr frequently advises companies from regulated industries – including from the healthcare and pharmaceutical sectors – on their projects and transactions. Clients include pharmaceutical companies, generics producers and medical device manufacturers.
Advisors to MediBeacon: Noerr LLP
Dr. Florian Becker (lead, Corporate/M&A, Munich), Prof. Dr. Sebastian Wündisch (IP Law, Dresden), Dr. Heidi Mahr (Employment & Pensions, Munich)
Associates: Theresa Arand (IP Law, Dresden), Dr. Kathrin Hoger (Corporate/M&A, Frankfurt), Julia Kominek (Private Equity & Venture Capital, Munich)